These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 27978552)
1. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552 [TBL] [Abstract][Full Text] [Related]
2. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739 [TBL] [Abstract][Full Text] [Related]
3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
4. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506 [TBL] [Abstract][Full Text] [Related]
7. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related]
11. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942 [TBL] [Abstract][Full Text] [Related]
12. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Masters GA; Wang X; Hodgson L; Shea T; Vokes E; Green M Lung Cancer; 2011 Nov; 74(2):258-63. PubMed ID: 21529989 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552 [TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer. Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842 [TBL] [Abstract][Full Text] [Related]
18. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812 [TBL] [Abstract][Full Text] [Related]
19. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer]. Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022 [TBL] [Abstract][Full Text] [Related]
20. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer]. Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]